Six very short weeks
I can’t believe it’s been less than six weeks since I wrote to you about a newfound HRT danger. Researchers discovered that breast cancer patients who use synthetic HRT appear to double their risk of dying from the disease.
Usually these waves of bad news about HRT are spaced by several months. But not this time.
At a recent cancer prevention research conference, a team from the UK’s Oxford University presented a study that examined nine years of medical records for nearly 127,000 post-menopausal women.
The Oxford team reports a “significantly increased risk” of ovarian cancer among women who used estrogen-only HRT for five or more years.
The lead author of the study told the conference “This study is consistent with previous recommendations that say if women are going to take hormones they should only take them in the short term.”
Yes, we’ve heard all about that “shortest possible time” business. It’s like a “Get Out of Jail Free” card for Pfizer, the maker of HRT drugs. If a woman takes HRT and develops breast cancer, ovarian cancer, dementia, heart attack, or stroke, why it’s not the drug’s fault! No. It’s HER fault. She took it too long.
But that very lame loophole is wearing very thin.
Dr. Peter B. Bach, of Memorial Sloan-Kettering Cancer Center recently told the New York Times that the “lowest possible dose for the shortest possible time” advice is questionable.
Questionable?! Knowing all we know about HRT, it’s irresponsible and bordering on criminal in my book!
Meanwhile, you will not believe what’s coming up next.
The Epoch Times reports that the National Institutes of Health are funding trials testing HRT in pre-menopausal women to see if the drug will help early menopausal symptoms without increasing serious risks.
Care to bet how THAT trial will go? Talk about grasping at straws!
Apart from the fact that many women in the trial will be put in danger, the worst part is the NIH participation. It means that our tax dollars are underwriting this desperate attempt by Pfizer executives to salvage something, ANYTHING, from the disaster of their pharmaceutical HRT.
“Menopausal hormone therapy and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition” Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, Abstract B101, November 7-10, 2010, aacr.org